Evidence map›Paper›PMID 39714577›Full record

ArticleEndocrine2025

Organ-specific response to [

Darejan Mamulashvili Bessac, Philippe Baltzinger, Nathan Poterszman, Floriane Pham Van, Cedric Collen, Gabriel G Malouf, Eric Ouvrard, Ashjan Kaseb, Clemence Porot, Meher Ben Abdelghani and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Normal organ [European journal of nuclear medicine and molecular imaging · 2026
    Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Darejan Mamulashvili BessacNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
Philippe BaltzingerEndocrinology, Diabetology, Nutrition, University Hospitals of Strasbourg, Strasbourg University, Strasbourg, France.
Nathan PoterszmanNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
Floriane Pham VanNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
Cedric CollenNuclear Medicine, Jean Minjoz University Hospital, Franche Compté University, Besançon, France.
Gabriel G MaloufOncology, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
Eric OuvrardNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
Ashjan KasebNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France.
Clemence PorotRadiopharmacy, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
Meher Ben AbdelghaniGastroenterology, Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
Pietro AddeoHepato-Pancreato-Biliary Surgery and Liver Transplantation, University Hospitals of Strasbourg, Strasbourg, France.
Luc MertzRadiophysics, University Hospitals of Strasbourg, Strasbourg, France.
Bernard GoichotEndocrinology, Diabetology, Nutrition, University Hospitals of Strasbourg, Strasbourg University, Strasbourg, France.
Alessio ImperialeNuclear Medicine and Molecular Imaging, Institut de Cancérologie Strasbourg Europe (ICANS), University Hospitals of Strasbourg, University of Strasbourg, Strasbourg, France. a.imperiale@icans.eu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate organ-specific response to [

methodsA retrospective analysis was conducted on 33 metastatic patients. PET/CT were performed pre-treatment (PET0), mid-treatment after two PRRT cycles (PET2), and post-treatment (PET4). SUV

resultsLiver metastases showed significant reduction in both SUV

conclusion[

Indexed as

Intestinal NeoplasmsIntestine, SmallNeuroendocrine TumorsOctreotideOrganometallic CompoundsRadiopharmaceuticalsAdultAgedBone NeoplasmsFemaleHumansLiver NeoplasmsMaleMiddle AgedPositron Emission Tomography Computed TomographyReceptors, Peptidelutetium Lu 177 dotatateOctreotideOrganometallic CompoundsRadiopharmaceuticalsReceptors, Peptide[177Lu]DOTATATE[68Ga]DOTATOCneuroendocrinepeptide receptor radionuclide therapyPETsmall intestine

Identifiers

PMID39714577

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.